Why I'm telling friends to avoid gold stocks

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

Chen Schor Biography and Net Worth

CEO of Adicet Bio

Mr. Schor has served as Adicet’s President, Chief Executive Officer and Director since its merger with resTORbio in September 2020. He held the role of President and Chief Executive Officer at resTORbio since co-founding the company in 2016. Mr. Schor has led biotech companies across all stages, from formation and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. Prior to co-founding resTORbio, Mr. Schor led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL). Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor holds an M.B.A., a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).

What is Chen Schor's net worth?: The estimated net worth of Chen Schor is at least $41,730.24 as of October 2nd, 2023. Mr. Schor owns 43,469 shares of Adicet Bio stock worth more than $41,730 as of December 26th. This net worth estimate does not reflect any other assets that Mr. Schor may own. Additionally, Mr. Schor receives a salary of $871,970.00 as CEO at Adicet Bio. Learn More about Chen Schor's net worth.
How old is Chen Schor?: Mr. Schor is currently 52 years old. There are 5 older executives and no younger executives at Adicet Bio. Learn More on Chen Schor's age.
What is Chen Schor's salary?: As the CEO of Adicet Bio, Inc., Mr. Schor earns $871,970.00 per year. Learn More on Chen Schor's salary.
How do I contact Chen Schor?: The corporate mailing address for Mr. Schor and other Adicet Bio executives is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. Adicet Bio can also be reached via phone at (650) 503-9095 and via email at [email protected]. Learn More on Chen Schor's contact information.
Has Chen Schor been buying or selling shares of Adicet Bio?: Chen Schor has not been actively trading shares of Adicet Bio in the last ninety days. Most recently, on Monday, October 2nd, Chen Schor bought 5,500 shares of Adicet Bio stock. The stock was acquired at an average cost of $1.33 per share, with a total value of $7,315.00. Following the completion of the transaction, the chief executive officer now directly owns 43,469 shares of the company's stock, valued at $57,813.77. Learn More on Chen Schor's trading history.
Who are Adicet Bio's active insiders?: Adicet Bio's insider roster includes Chen BA (), Jay Elliott (COO), Aya Jakobovits (Director), Chen Schor (CEO), and Andrew Sinclair (Director). Learn More on Adicet Bio's active insiders.
Are insiders buying or selling shares of Adicet Bio?: In the last twelve months, Adicet Bio insiders bought shares 1 times. They purchased a total of 3,125,000 shares worth more than $7,500,000.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 5,900 shares worth more than $8,437.00. The most recent insider tranaction occured on June, 5th when Director Michael Kauffman sold 5,900 shares worth more than $8,437.00. Insiders at Adicet Bio own 19.1% of the company. Learn More about insider trades at Adicet Bio.
Information on this page was last updated on 6/5/2024.

Chen Schor Insider Trading History at Adicet Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/2/2023	Buy	5,500	$1.33	$7,315.00	43,469
9/28/2023	Buy	5,500	$1.42	$7,810.00	182,469
11/10/2022	Sell	9,955	$21.03	$209,353.65	91,469
11/2/2022	Sell	500	$18.00	$9,000.00	138,237
9/14/2022	Sell	952	$18.00	$17,136.00	138,737
9/12/2022	Sell	66,947	$16.77	$1,122,701.19	122,712
9/9/2022	Sell	8,094	$16.51	$133,631.94	66,747
6/16/2021	Sell	16,466	$10.53	$173,386.98
6/3/2021	Sell	16,466	$12.06	$198,579.96
5/19/2021	Sell	16,466	$13.45	$221,467.70
4/20/2021	Sell	16,466	$12.01	$197,756.66
4/6/2021	Sell	16,466	$13.04	$214,716.64
3/16/2021	Sell	16,466	$15.34	$252,588.44

Chen Schor Buying and Selling Activity at Adicet Bio

Adicet Bio Company Overview

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Today's Range

Now: $0.96

$0.88

$0.96

50 Day Range

MA: $1.13

$0.86

$1.52

2 Week Range

Now: $0.96

$0.81

$3.77

Volume

316,510 shs

Average Volume

1,070,182 shs

Market Capitalization

$79.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88

Why I'm telling friends to avoid gold stocks

From DTI | Ad

And if you’d like to get your hands on this, here you go, the complete breakdown.

Chen Schor Biography and Net Worth

What is Chen Schor's net worth?

How old is Chen Schor?

What is Chen Schor's salary?

How do I contact Chen Schor?

Has Chen Schor been buying or selling shares of Adicet Bio?

Who are Adicet Bio's active insiders?

Are insiders buying or selling shares of Adicet Bio?